Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654751 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
A Phase 4 study, sponsored by Janssen Research & Development.
- Not yet
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT07654751 is a Phase 4 study that has not yet begun recruiting, run by Janssen Research & Development. The registered enrollment target is 10 participants.
The verdict
NCT07654751, a Phase 4 study, has not yet begun recruiting, sponsored by Janssen Research & Development.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.
Interventions
- DRUG Guselkumab
- PROCEDURE Breast Milk Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07654751
The ClinicalTrials.gov registry entry for NCT07654751 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guselkumab is the first listed.
NCT07654751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07654751 about?
NCT07654751 is a clinical study titled "A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically". The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.
What is the current status of trial NCT07654751?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2026-06-15. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07654751?
The interventions under investigation include: Guselkumab (DRUG), Breast Milk Sample Collection (PROCEDURE).
Who is sponsoring clinical trial NCT07654751?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.